APL-501

BIOLOGICAL2 trials

Sponsors

Apollomics (Australia) Pty. Ltd.

Conditions

Cancer of Unknown Primary SiteHepatocellular CarcinomaMicrosatellite InstabilityMismatch Repair DeficiencyRenal Cell CarcinomaSolid Tumor

Phase 1

APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors

CompletedNCT03053466

Apollomics (Australia) Pty. Ltd.Cancer of Unknown Primary Site, Microsatellite Instability, Mismatch Repair Deficiency +1

Start: 2017-03-27End: 2022-02-25Updated: 2022-05-09

APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC

TerminatedNCT03655613

Apollomics (Australia) Pty. Ltd.Hepatocellular Carcinoma, Renal Cell Carcinoma

Start: 2018-09-05End: 2021-12-15Updated: 2022-05-06

Related Papers

A phase I study of APL-501, an anti-PD-1 antibody, in patients with recurrent or advanced solid tumors.

Journal of Clinical Oncology2020-05-20